Meeting
2018 ASCO Annual Meeting
Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.
Authors
Tuba Nur Gide
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
Tuba Nur Gide , Camelia Quek , Alexander M. Menzies , Jason Madore , Rebecca Velickovic , Matthew Wongchenko , Yibing Yan , Matteo S. Carlino , Alexander David Guminski , Robyn Saw , Ines Silva , Umaimainthan Palendira , John F. Thompson , Richard A. Scolyer , Georgina V. Long , James S. Wilmott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9518)
DOI
10.1200/JCO.2018.36.15_suppl.9518
Abstract #
9518
Poster Bd #
345
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris